*The only drug currently approved for this indication is Ranibizuamb.
Pegaptanib and Bevacizumab are used off-label**Corticoids are used off-label. This applies to both intravenous triamcinolone and implantable slow-release devices ***Assuming patient attendance is possible |
| Figure 4: Treatment algorithm for diffuse and mixed macular edema. |